TLD1433 Photosensitizer Inhibits Conjunctival Melanoma Cells in Zebrafish Ectopic and Orthotopic Tumour Models

The ruthenium-based photosensitizer (PS) TLD1433 has completed a phase I clinical trial for photodynamic therapy (PDT) treatment of bladder cancer. Here, we investigated a possible repurposing of this drug for treatment of conjunctival melanoma (CM). CM is a rare but often deadly ocular cancer. The...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Quanchi, Ramu, Vadde, Aydar, Yasmin, Groenewoud, Arwin, Zhou, Xue-Quan, Jager, Martine J., Cole, Houston, Cameron, Colin G., McFarland, Sherri A., Bonnet, Sylvestre, Snaar-Jagalska, B. Ewa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7139549/
https://www.ncbi.nlm.nih.gov/pubmed/32143295
http://dx.doi.org/10.3390/cancers12030587

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7139549/
https://www.ncbi.nlm.nih.gov/pubmed/32143295
http://dx.doi.org/10.3390/cancers12030587

Ejemplares similares